China State Institute of Pharmaceutical Industry and Jiangsu Nhwa Pharmaceutical Co. Ltd. have jointly described aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivatives acting as serotonin 5-HT1A and/or dopamine D2 and/or D3 receptor agonists reported to be useful for the treatment of Parkinson’s disease.